ClinicalTrials.Veeva

Menu

Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery (Maigrir_OT)

C

Centre Hospitalier Universitaire de Nice

Status

Enrolling

Conditions

Obesity

Treatments

Other: Blood GLP1
Other: Blood No treated GLP1

Study type

Interventional

Funder types

Other

Identifiers

NCT06278285
21-AOIP-01

Details and patient eligibility

About

Normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. Above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. To this end, the investigators will first study the impact of GLP-1 analogues on adipose tissue. The main objective is to show that subjects treated with a GLP-1 agonist have a significant change in their oxytocin levels compared with subjects not treated with a GLP-1 agonist.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient over 18 years of age.
  • Patient able to read and understand the information/consent leaflet.
  • Patient with BMI > 35 with at least one comorbidity. Or BMI > 40
  • Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM.
  • Membership of a social security scheme
  • Patient's signed informed consent
  • For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months.
  • For non-GLP-1 analogue group: never taken GLP-1 analogues.

Exclusion criteria

  • Pregnant or breast-feeding women.
  • Vulnerable patients (under guardianship)
  • Patients deprived of liberty

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

40 participants in 2 patient groups

whole blood in a GLP1
Other group
Description:
Oxytocyne assay in a GLP1 analogue or non-analogue patient population
Treatment:
Other: Blood GLP1
whole blood in non analague patient population
Other group
Description:
Oxytocyne assay in a GLP1 analogue or non-analogue patient population
Treatment:
Other: Blood No treated GLP1

Trial contacts and locations

1

Loading...

Central trial contact

Iannelli Antonio, PhD; ROUX Christian, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems